Physician profile
Bruce Abraham
NPI 1467601914
$2,076.78
in general payments reported to CMS, 2019-2025
15 companies · $1,341 in 2025
The $1,341 reported for 2025 was more than what 85% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $108 · 2022: $52.62 · 2023: $194 · 2024: $381 · 2025: $1,341.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,349 · Travel and Lodging: $567.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,348.95 |
| Travel and Lodging | $567.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,259.23 | 2022-2025 | Wavewriter Alpha Prime 16, General - Pain Management |
| Collegium Pharmaceutical, INC. | $416.13 | 2022-2025 | Belbuca, Xtampza |
| Abbvie INC. | $91.43 | 2023-2024 | Ubrelvy, Qulipta |
| Medtronic, INC. | $76.65 | 2021 | |
| Orexo US, INC. | $46.12 | 2022-2023 | Zubsolv |
| Protega Pharmaceutials INC | $35.81 | 2024 | Roxybond |
| Tonix Medicines, INC. | $24.38 | 2025 | Tonmya |
| Vertex Pharmaceuticals Incorporated | $19.81 | 2025 | |
| Alkermes, INC. | $17.67 | 2023 | Vivitrol |
| Redhill Biopharma INC. | $17.07 | 2021 | |
| Scilex Pharmaceuticals INC. | $15.96 | 2023 | Ztlido |
| Valinor Pharma, LLC | $15.08 | 2025 | Movantik |
| Biodelivery Sciences International, INC. | $14.45 | 2021 | |
| Indivior INC. | $13.99 | 2023 | Sublocade |
| Braeburn INC. | $13.00 | 2023 | Brixadi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bruce Abraham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.